PS
| |
Patient Square Capital LP13F | |
| Patient Square Capital LP | |
| Last update 2024-11-14 | 11 Stocks (9 new) |
| Value $269.00 Mil | Turnover 21 % |
| Portfolio Report | |
Patient Square Capital LP Top Holdings of 2024-09-30
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ROIV | Roivant Sciences Ltd | 12,228,465 | 141116.490 | 0% | 52.380 | 0% | 1.650 | -8.31% | -7.23% | 8058.407 | Biotechnology | |
LQDA | Liquidia Corp | 7,182,532 | 71825.320 | 0% | 26.660 | 0% | 8.510 | +5.72% | +4.55% | 1050.765 | Biotechnology | |
CGEM | Cullinan Therapeutics Inc | 824,705 | 13805.560 | New Holding | 5.120 | +5.12% | 1.420 | -41.96% | -16.09% | 596.832 | Biotechnology | |
INSM | Insmed Inc | 171,704 | 12534.390 | New Holding | 4.650 | +4.65% | 0.100 | -7.48% | +2.72% | 12723.560 | Biotechnology | |
EYPT | EyePoint Pharmaceuticals Inc | 1,361,979 | 10882.210 | New Holding | 4.040 | +4.04% | 2.000 | -29.34% | +6.98% | 531.920 | Biotechnology | |
NRIX | Nurix Therapeutics Inc | 325,789 | 7320.480 | New Holding | 2.720 | +2.72% | 0.460 | -23.83% | +4.35% | 1403.974 | Biotechnology | |
PHVS | Pharvaris NV | 242,341 | 4488.160 | New Holding | 1.670 | +1.67% | 0.450 | -23.56% | -14.27% | 882.769 | Biotechnology | |
NTLA | Intellia Therapeutics Inc | 128,569 | 2642.090 | New Holding | 0.980 | +0.98% | 0.130 | -54.37% | -19.47% | 956.480 | Biotechnology | |
ELVN | Enliven Therapeutics Inc | 90,572 | 2313.210 | New Holding | 0.860 | +0.86% | 0.190 | -22.60% | -3.27% | 1070.260 | Biotechnology | |
OCUL | Ocular Therapeutix Inc | 235,498 | 2048.830 | New Holding | 0.760 | +0.76% | 0.150 | -29.12% | -4.80% | 1282.896 | Biotechnology |
Patient Square Capital LP's Historical Top Holdings Breakdowns
Patient Square Capital LP's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
LQDA | Liquidia Corp | 2024-03-31 | New Buy | +45.11% | 11.35 ($13.9) 16.73 | $12.41 | -10.68% | New holding | 7,182,532 | 7,182,532 | |
ROIV | Roivant Sciences Ltd | 2023-06-30 | Add | +28.53% | 7.09 ($8.92) 10.08 | $11.07 | 24.10% | Add 85.17% | 12,639,920 | 5,813,953 | |
EAR | Eargo Inc | 2024-03-31 | Sold Out | -22.40% | 2.57 ($2.63) 2.79 | $2.57 | -2.28% | Sold Out | 0 | -15,821,299 | |
CGEM | Cullinan Therapeutics Inc | 2024-09-30 | New Buy | +5.12% | 16.03 ($17.74) 20.86 | $10.25 | -42.22% | New holding | 824,705 | 824,705 | |
INSM | Insmed Inc | 2024-09-30 | New Buy | +4.65% | 62 ($73.8) 79.01 | $71.12 | -3.63% | New holding | 171,704 | 171,704 | |
EYPT | EyePoint Pharmaceuticals Inc | 2024-09-30 | New Buy | +4.04% | 7.58 ($8.78) 10.54 | $7.79 | -11.23% | New holding | 1,361,979 | 1,361,979 | |
NRIX | Nurix Therapeutics Inc | 2024-09-30 | New Buy | +2.72% | 18.93 ($22.65) 25.69 | $19.82 | -12.49% | New holding | 325,789 | 325,789 | |
ROIV | Roivant Sciences Ltd | 2024-03-31 | Reduce | -2.53% | 9.87 ($10.78) 11.8 | $11.07 | 2.69% | Reduce -3.26% | 12,228,465 | -411,455 | |
PHVS | Pharvaris NV | 2024-09-30 | New Buy | +1.67% | 15.73 ($18.27) 21.4 | $16.28 | -10.91% | New holding | 242,341 | 242,341 | |
NTLA | Intellia Therapeutics Inc | 2024-09-30 | New Buy | +0.98% | 19.72 ($23.06) 27.36 | $9.39 | -59.27% | New holding | 128,569 | 128,569 |
Patient Square Capital LP Total Holding History ($B)
Patient Square Capital LP's Asset Allocation
Patient Square Capital LP Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
Patient Square Capital LP's Hypothetical Growth since 2024-09-30
Patient Square Capital LP's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
Patient Square Capital LP's Holdings Heat Map
Size field:
Patient Square Capital LP's Holdings Bubble Chart
Patient Square Capital LP News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers